Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

HeartSciences (HSCS) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for HeartSciences (HSCS) over the last 5 years, with Q4 2025 value amounting to $2.8 million.

  • HeartSciences' Shares Outstanding (Weighted Average) rose 20306.95% to $2.8 million in Q4 2025 from the same period last year, while for Oct 2025 it was $2.8 million, marking a year-over-year increase of 20306.95%. This contributed to the annual value of $938257.0 for FY2025, which is 16615.71% up from last year.
  • As of Q4 2025, HeartSciences' Shares Outstanding (Weighted Average) stood at $2.8 million, which was up 20306.95% from $1.3 million recorded in Q3 2025.
  • In the past 5 years, HeartSciences' Shares Outstanding (Weighted Average) ranged from a high of $8.2 million in Q1 2023 and a low of $740.0 during Q2 2021
  • Its 5-year average for Shares Outstanding (Weighted Average) is $2.3 million, with a median of $986057.0 in 2025.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 44839891.89% in 2022, then tumbled by 9866.22% in 2023.
  • Over the past 5 years, HeartSciences' Shares Outstanding (Weighted Average) (Quarter) stood at $3.3 million in 2021, then skyrocketed by 147.76% to $8.2 million in 2022, then tumbled by 98.66% to $109841.0 in 2023, then surged by 735.25% to $917445.0 in 2024, then soared by 203.07% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q4 2025, $1.3 million for Q3 2025, and $938257.0 during Q2 2025.